Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Mar. 31, 2023
Current assets:
Cash and cash equivalents	$ 1,408,231	$ 1,676,813
Other current assets	143,396	121,774
Total current assets	1,551,627	1,798,587
Property and equipment, net	24,477	39,086
Operating lease right-of-use assets	48,629	53,251
Investments measured at fair value	250,393	304,317
Intangible assets, net	140,621	144,881
Other assets	49,796	49,482
Total assets	2,065,543	2,389,604
Current liabilities:
Accounts payable	44,123	37,830
Accrued expenses	152,923	167,129
Operating lease liabilities	10,903	11,693
Current portion of long-term debt (includes $28,120 and $26,940 accounted for under the fair value option at September 30, 2023 and March 31, 2023, respectively)	48,998	40,720
Other current liabilities	8,599	15,076
Total current liabilities	265,546	272,448
Liability instruments measured at fair value	31,114	63,546
Operating lease liabilities, noncurrent	48,630	53,476
Long-term debt, net of current portion (includes $188,911 and $180,700 accounted for under the fair value option at September 30, 2023 and March 31, 2023, respectively)	389,445	375,515
Other liabilities	5,175	17,032
Total liabilities	739,910	782,017
Commitments and contingencies (Note 11)
Shareholders' equity:
Common shares, par value $0.0000000341740141 per share, 7,000,000,000 shares authorized and 800,792,365 and 760,143,393 shares issued and outstanding at September 30, 2023 and March 31, 2023, respectively	0	0
Additional paid-in capital	5,320,503	4,933,137
Accumulated deficit	(4,368,897)	(3,772,754)
Accumulated other comprehensive loss	(3,072)	(2,617)
Shareholders' equity attributable to Roivant Sciences Ltd.	948,534	1,157,766
Noncontrolling interests	377,099	449,821
Total shareholders' equity	1,325,633	1,607,587
Total liabilities and shareholders' equity	$ 2,065,543	$ 2,389,604